Esperion Therapeutics, Inc. (ESPR)
After hours:
| Previous Close | 1.9600 |
| Open | 1.9800 |
| Bid | 2.1000 x 3000 |
| Ask | 2.1700 x 3000 |
| Day's Range | 1.9350 - 2.1700 |
| 52 Week Range | 0.7000 - 3.4000 |
| Volume | |
| Avg. Volume | 4,286,267 |
| Market Cap | 423.846M |
| Beta (5Y Monthly) | 1.00 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.8500 |
| Earnings Date | Nov 05, 2024 - Nov 11, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.59 |
Insider MonkeyIs Esperion Therapeutics, Inc. (ESPR) the Best NASDAQ Stock Under $5?
We recently compiled a list of 7 Best NASDAQ Stocks Under $5. In this article, we will look at where Esperion Therapeutics, Inc. (NASDAQ:ESPR) ranks among the best NASDAQ stocks under $5. Job Market Cools Yet Economists Remain Optimistic About Stability A Yahoo Finance report on September 28 reveals that consumers are beginning to feel […]
GlobeNewswireEsperion EU Partner Reports Final Real-World Results from MILOS German Cohort Demonstrating Strong Increase in LDL-C Goal Achievement With Addition of Bempedoic Acid
– Patients Prescribed Bempedoic Acid, As Well As Bempedoic Acid and Ezetimibe, With or Without Other Lipid Lowering Therapies, Showed A One-Third Relative Reduction in Low-Density LDL-C From Pre-Treatment To 2-Years in the MILOS Study – – Real-World Results Demonstrated ~7-Fold Increase in Proportion of Patients Achieving LDL-C Goals When Treated With Bempedoic Acid or Bempedoic Acid and Ezetimibe – – Data From the MILOS German Cohort Showed Bempedoic Acid, Alone or With Ezetimibe, Was Effective
- GlobeNewswire
Esperion Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
ANN ARBOR, Mich., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on September 23, 2024, the Company granted one new employee 3,500 restricted stock units (RSUs) under Esperion’s 2017 Inducement Equity Incentive Plan. The 2017 Inducement Equity Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Esperion (or following a bona fide period of non-employment), as an inducement
